The Boundaries Between Wellness Products and Medical Devices
By Deborah Borfitz November 5, 2026 | A Food and Drug Administration (FDA) warning letter issued to Whoop last year set off a regulatory dispute reshaping how the agency draws...
Read More
The Breathtaking New Cure for Chronic Insomniacs
Contributed Commentary by Barry Krakow, MD October 22, 2026 | Chronic insomnia (difficulty falling asleep or staying asleep) is a devilishly tricky condition to treat, and for millions cures remain...
Read More
LinusBio’s Traced Uses Hair to Build a Molecular Record of Environmental Exposures
By Allison Proffitt September 8, 2026 | LinusBio is delving into the exposome with Traced, a new hair testing tool designed to give consumers a month-long view of their exposure...
Read More
AI Helps Find ‘Hidden Gems’ Buried in Sleep Study Data
By Deborah Borfitz For decades now, doctors have been referring people suspected of having obstructive sleep apnea to a specialized medical facility for a polysomnogram (PSG). The gold-standard overnight test...
Read More
Guidelines on Navigating GLP-1 Medications Before, During, and After Pregnancy
By Irene Yeh As incretin-based medications, including glucagon-like peptide-1 receptor agonists (GLP-1RAs) or glucose-dependent insulinotropic polypeptide (GIP) drugs, become increasingly common in obesity and weight management, questions remain about their...
Read More
Management of Co-Occurring Conditions of Down Syndrome Becoming More Personalized
By Deborah Borfitz Medical conditions vary widely in presentation, progression, and treatment response, with Down syndrome standing out as one of the most variable of all. The genetic occurrence, caused...
Read More
Rethinking Pregnancy Nutrition: The Overlooked Issue of Environmental Chemical Exposure
By Irene Yeh Eating a healthy diet during pregnancy may come with an unexpected tradeoff: some foods recommended for good nutrition can also be sources of environmental chemical exposure. The...
Read More
Beyond Weight Loss: GLP-1 Drugs Enter the Eating Disorder Conversation
By Irene Yeh Originally developed to treat type 2 diabetes and later for obesity management, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are rapidly expanding into other areas of treatment. Researchers...
Read More